A preclinical study focused on the efficacy of a nanobody agent that selectively redirects anti-dinitrophenyl (DNP) antibodies to the surface of HER2+ BC cells, resulting in their targeted destruction by ADCC. The gene discussed is ERBB2; the disease is breast cancer.